Predicting sensitivity of non-small-cell lung cancer to gefitinib: Is there a role for P-akt?

[1] Bailey L. Renee, 2003, Proceedings of the American Association for Cancer Research Annual Meeting, V44, P1362

[2] Studies leading to the identification of ZD1839 (Iressa™):: An orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer [J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2001, 11 (14) : 1911 - 1914

[3] Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2004, 96 (15): : 1133 - 1141

[4] FRANKLIN WA, 2004, P AN M AM SOC CLIN, V23, P618

[5] Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer [J]. JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (12) : 2237 - 2246

[6] Epidermal growth factor receptor: mechanisms of activation and signalling [J]. EXPERIMENTAL CELL RESEARCH, 2003, 284 (01) : 31 - 53

[7] Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer - A randomized trial [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2003, 290 (16): : 2149 - 2158

[8] Non-small cell lung cancers frequently express phosphorylated Akt; an immunohistochemical study [J]. APMIS, 2002, 110 (7-8) : 587 - 592

[9] Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (21) : 2129 - 2139

[10] Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer [J]. JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (14) : 2787 - 2799

[1] Bailey L. Renee, 2003, Proceedings of the American Association for Cancer Research Annual Meeting, V44, P1362

[2] Studies leading to the identification of ZD1839 (Iressa™):: An orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer [J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2001, 11 (14) : 1911 - 1914

[3] Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2004, 96 (15): : 1133 - 1141

[4] FRANKLIN WA, 2004, P AN M AM SOC CLIN, V23, P618

[5] Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer [J]. JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (12) : 2237 - 2246

[6] Epidermal growth factor receptor: mechanisms of activation and signalling [J]. EXPERIMENTAL CELL RESEARCH, 2003, 284 (01) : 31 - 53

[7] Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer - A randomized trial [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2003, 290 (16): : 2149 - 2158

[8] Non-small cell lung cancers frequently express phosphorylated Akt; an immunohistochemical study [J]. APMIS, 2002, 110 (7-8) : 587 - 592

[9] Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (21) : 2129 - 2139

[10] Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer [J]. JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (14) : 2787 - 2799